Ross RJ - Search Results

1

Binding and functional studies with the growth hormone receptor antagonist, B2036-PEG (pegvisomant), reveal effects of pegylation and evidence that it binds to a receptor dimer.

Ross RJ, Leung KC, Maamra M, Bennett W, Doyle N, Waters MJ, Ho KK. Ross RJ, et al. J Clin Endocrinol Metab. 2001 Apr;86(4):1716-23. doi: 10.1210/jcem.86.4.7403. J Clin Endocrinol Metab. 2001. PMID: 11297608

2

Administration of human recombinant insulin-like growth factor-I to patients following major gastrointestinal surgery.

Miell JP, Taylor AM, Jones J, Buchanan CR, Rennie J, Sherwood R, Leicester R, Ross RJ. Miell JP, et al. Among authors: ross rj. Clin Endocrinol (Oxf). 1992 Dec;37(6):542-51. doi: 10.1111/j.1365-2265.1992.tb01486.x. Clin Endocrinol (Oxf). 1992. PMID: 1283730 Clinical Trial.

3

The induction of a specific protease for insulin-like growth factor binding protein-3 in the circulation during severe illness.

Davies SC, Wass JA, Ross RJ, Cotterill AM, Buchanan CR, Coulson VJ, Holly JM. Davies SC, et al. Among authors: ross rj. J Endocrinol. 1991 Sep;130(3):469-73. doi: 10.1677/joe.0.1300469. J Endocrinol. 1991. PMID: 1719118

4

Levels of GH binding activity, IGFBP-1, insulin, blood glucose and cortisol in intensive care patients.

Ross RJ, Miell JP, Holly JM, Maheshwari H, Norman M, Abdulla AF, Buchanan CR. Ross RJ, et al. Clin Endocrinol (Oxf). 1991 Oct;35(4):361-7. doi: 10.1111/j.1365-2265.1991.tb03549.x. Clin Endocrinol (Oxf). 1991. PMID: 1721565

5

Critically ill patients have high basal growth hormone levels with attenuated oscillatory activity associated with low levels of insulin-like growth factor-I.

Ross R, Miell J, Freeman E, Jones J, Matthews D, Preece M, Buchanan C. Ross R, et al. Clin Endocrinol (Oxf). 1991 Jul;35(1):47-54. doi: 10.1111/j.1365-2265.1991.tb03495.x. Clin Endocrinol (Oxf). 1991. PMID: 1909610

6

Pyridostigmine fails to increase either spontaneous or GHRH-stimulated GH secretion during day or night in growth hormone-insufficient children.

Kirk JM, Ross RJ, Trainer PJ, Froud AL, Davies SC, Savage MO, Besser GM. Kirk JM, et al. Among authors: ross rj. Clin Endocrinol (Oxf). 1991 May;34(5):407-11. doi: 10.1111/j.1365-2265.1991.tb00313.x. Clin Endocrinol (Oxf). 1991. PMID: 2060150 Clinical Trial.

7

Subcutaneous growth hormone-releasing hormone augments pulsatile nocturnal GH release in GH-insufficient children, but may also raise basal GH secretion.

Ross RJ, Kirk JM, Tsagarakis S, Trainer PJ, Ciccarelli E, Touzel R, Grossman A, Savage MO, Besser GM. Ross RJ, et al. Clin Endocrinol (Oxf). 1990 Aug;33(2):239-48. doi: 10.1111/j.1365-2265.1990.tb00488.x. Clin Endocrinol (Oxf). 1990. PMID: 2225481 Clinical Trial.

8

Opioids stimulate growth hormone (GH) release in man independently of GH-releasing hormone.

Delitala G, Tomasi PA, Palermo M, Ross RJ, Grossman A, Besser GM. Delitala G, et al. Among authors: ross rj. J Clin Endocrinol Metab. 1989 Aug;69(2):356-8. doi: 10.1210/jcem-69-2-356. J Clin Endocrinol Metab. 1989. PMID: 2546963

9

GH feedback occurs through modulation of hypothalamic somatostatin under cholinergic control: studies with pyridostigmine and GHRH.

Ross RJ, Tsagarakis S, Grossman A, Nhagafoong L, Touzel RJ, Rees LH, Besser GM. Ross RJ, et al. Clin Endocrinol (Oxf). 1987 Dec;27(6):727-33. doi: 10.1111/j.1365-2265.1987.tb02957.x. Clin Endocrinol (Oxf). 1987. PMID: 2901302 Clinical Trial.

10

Growth hormone pretreatment in man blocks the response to growth hormone-releasing hormone; evidence for a direct effect of growth hormone.

Ross RJ, Borges F, Grossman A, Smith R, Ngahfoong L, Rees LH, Savage MO, Besser GM. Ross RJ, et al. Clin Endocrinol (Oxf). 1987 Jan;26(1):117-23. doi: 10.1111/j.1365-2265.1987.tb03645.x. Clin Endocrinol (Oxf). 1987. PMID: 3100110 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results